Compare Tyson Foods, Inc. (TSN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs GeneDx Holdings Corp — how do they compare? Tyson Foods, Inc. trades at $53.43 (market cap $18.41B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Tyson Foods, Inc. is far larger — about 9.1× GeneDx Holdings Corp's market cap, and Tyson Foods, Inc. pays a 3.9% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tyson Foods, Inc. for 76 Days and GeneDx Holdings Corp for 19 Days on average.
| TSN | WGS | |
|---|---|---|
Market Cap | $18.41B | $2.02B |
Volume | 3,757,599 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $167.51 |
52-Week Low | $50.47 | $34.51 |
Typical Hold Time | 76 Days | 19 Days |
Enterprise Value | $25.68B | $2.05B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $52.34, up 1.24% on the day, with a bullish technical signal but mixed earnings history including a recent Q4 2025 miss. Valuation ratios like P/S of 0.33 appear attractive, but thin net margins of 1.03% and ongoing cash flow challenges highlight operational pressures. Recent news includes a lowered fiscal 2026 outlook and a securities investigation, adding uncertainty despite insider buying and institutional interest.
The stock offers a potential 25% upside to the consensus price target of $65.40, supported by a majority analyst buy rating. However, risks are elevated from beef segment losses, negative cash flows, and legal scrutiny. Investor sentiment is cautious amid guidance cuts, making earnings execution critical for near-term direction.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
